OIE Reference Laboratory Reports Activities Activities in 2015

This report has been submitted : 2016-01-20 13:49:59

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:

Foot and mouth disease

Address of laboratory:

Av. Romulo Joviano s/n (c/o LANAGRO) 33600-000 Pedro Leopoldo, MG Brazil

Tel.:

+55-21 36.61.90.64

Fax:

+55-21 36.61.90.01

E-mail address:

[email protected]

Website:

www.panaftosa.org

Name (including Title) of Head of Laboratory (Responsible Official):

Ottorino Cosivi, Medico Veterinario Director Centro Panamericando de Fiebre Aftosa -PANAFTOSAPAHO/WHO

Name (including Title and Position) of OIE Reference Expert:

Rossana Allende

Which of the following defines your laboratory? Check all that apply:

Other: United Nations Agency

OIE Reference Laboratory Reports Activities, 2015

1

Foot and mouth disease - Rossana Allende - brazil

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training) Yes

Diagnostic Test

Indicated in OIE Manual (Yes/No)

Total number of test performed last year

Indirect diagnostic tests I-ELISA 3ABC/EITB

yes

Direct diagnostic tests

Nationally

Internationally

0

304

Nationally

Internationally

RT-PCR gen 3D

yes

0

78

Viral isolation

yes

0

13

Ag ELISA

yes

0

13

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards. To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE? Yes NOTE: Currently, there are 22 laboratories that produce Standard Reference Reagents officially recognised by the OIE for 19 diseases/pathogens. Please click the following link to the list of OIE-approved International Standard Sera: http://www.oie.int/en/our-scientific-expertise/veterinary-products/reference-reagents/. If the reagent is not listed on this page, it is NOT considered OIE-approved. The next two questions allow you to indicate non-OIE-approved diagnostic reagents.

OIE-approved SRR producing laboratory – Select your lab from list:

2

OIE Reference Laboratory Reports Activities, 2015

Foot and mouth disease - Rossana Allende - brazil Disease

Foot and mouth disease

Type of reagent available

I-ELISA 3ABC/EITB

Test

Available from

Nonstructural protein tests

Related diagnostic test

non structural protein Ab test

Dr Rossana Allende Centro Panamericano de Fiebre Aftosa OPS/OMS, Av. President Kennedy 7778, Sao Bento, Duque de Caxias, ZC 25040-004 Rio de Janeiro, Brazil Tel: (55-21) 36.61.90.64 Fax: (55-21) 36.61.90.01 [email protected]

Produced/ Supply imported

produced

Amount supplied nationally (ml, mg)

500mL

Amount supplied internationally (ml, mg)

500mL

Name of recipient OIE Member Countries ARGENTINA BRAZIL CHILE COLOMBIA ECUADOR PARAGUAY PERU URUGUAY VENEZUELA

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries? Yes

OIE Reference Laboratory Reports Activities, 2015

3

Foot and mouth disease - Rossana Allende - brazil

Type of reagent available

Related diagnostic test

Produced/ provide

Amount supplied nationally (ml, mg)

Amount supplied internationally (ml, mg)

No. of recipient OIE Member Countries

Region of recipients

Africa America s Ag Typing ELISA

FMD/VSV Antigen typing

produced

non applicable

7,800.00 tests

6

Asia and Pacific Europe Middle East Africa America s

LP cELISA

FMD antibody detecton

produced

non applicable

474,000.00

8

Asia and Pacific Europe Middle East Africa America

Cell seeds

viral isolation/vaccine production

s produced

non applicable

30 mL

2

Asia and Pacific Europe Middle East Africa America s

Viral seeds

Production of reference antigen

produced

non applicable

15 mL

2

Asia and Pacific Europe Middle East Africa America

PCR positive control FMD

s PCR

produced

non applicable

110 mL

14

Asia and Pacific Europe Middle East

4. Did your laboratory produce vaccines? No

5. Did your laboratory supply vaccines to OIE Member Countries? No

4

OIE Reference Laboratory Reports Activities, 2015

Foot and mouth disease - Rossana Allende - brazil

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease? No 7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease? No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries? Yes

Name of OIE Member Country seeking assistance

Date (month)

No. samples received for provision of diagnostic support

No. samples received for provision of confirmatory diagnoses

BRAZIL

september-december

304 sera

0

BRAZIL

march

13 epithelial tissue

0

VENEZUELA

november

2

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country? Yes Name of the OIE Member Country receiving a technical consultancy

Purpose

How the advice was provided

VENEZUELA

FMD diagnostic and vaccine quality control

technical advice in situ

PARAGUAY

FMD vaccine quality control

technical advice in situ

BRAZIL

FMD differential diagnostic

technical advice in situ

COLOMBIA

FMD interpretation of NSP antibodies tests

Phone conferences

OIE Reference Laboratory Reports Activities, 2015

5

Foot and mouth disease - Rossana Allende - brazil

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own? Yes

Title of the study

Duration

Purpose of the study

Partners (Institutions)

FMD post vaccination monitoring

1 year

Verify level of herd immunity

INSAI/Venezuela and INIA/Venezuela

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control? Yes 12. Did your laboratory disseminate epizootiological data that had been processed and analysed? Yes

13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category) a) Articles published in peer-reviewed journals: 1 Clavijo A, Sanchez-Vazquez MJ, Buzanovsky LP, Martini M, Pompei JC, Cosivi O. Current status and future prospects to achieve foot-and-mouth disease eradication in South America. Transbound Emerg Dis. 2015 Mar. b) International conferences: 19 Centro Panamericano de Fiebre Aftosa. Informe de situación de los programas de erradicación de la fiebre aftosa. Sudamérica y Panamá, año 2014. Rio de Janeiro; PANAFTOSA-OPS/OMS; 2015. 114 p. http://bvs1.panaftosa.org.br/local/file/textoc/Sit2014esp.pdf

Centro Panamericano de Fiebre Aftosa. 5ª Reunión Extraordinaria de la Comisión Sudamericana de la Lucha Contra la Fiebre Aftosa. Resoluciones. Cuiabá, Mato Grosso, 19 de octubre del 2015. http://www.panaftosa.org/cosalfaextra5/dmdocuments/RESOLUCOES_5aCOSALFAExtr_[261015].pdf Centro Panamericano de Fiebre Aftosa. 42. Reunión Ordinária de la Comisión Sudamericana para la Lucha contra la Fiebre Aftosa (COSALFA 42): informe final. Quito, Ecuador, 16-17 abr. 2015. http://bvs1.panaftosa.org.br/local/File/textoc/cosalfa2015esp.pdf Centro Panamericano de Fiebre Aftosa. Seminario Internacional Pre COSALFA “Consolidando el Estatus Libre de Fiebre Aftosa de la Región de Sudamérica: Planes de Prevención, Vigilancia y Contingencia”. Quito, Ecuador, 13-14 abr. 2015. Allende R. Reporte de la Cooperación Técnica (CT) de PANAFTOSA en Fiebre Aftosa – año 2014. Laboratorio de Referencia. Presentado en Centro Panamericano de Fiebre Aftosa. 42. Reunión Ordinaria de la Comisión

6

OIE Reference Laboratory Reports Activities, 2015

Foot and mouth disease - Rossana Allende - brazil Sudamericana para la Lucha contra la Fiebre Aftosa (COSALFA 42). Quito, Ecuador, 16-17 abr. 2015. http://www.panaftosa.org/cosalfa42/dmdocuments/4%20COSALFA%2042%20Reporte%20Cooperacion%20Labor% 20Referencia_RA.pdf Allende R. Reporte de PANAFTOSA sobre el Proyecto “Banco Regional de antígenos/vacuna de Fiebre Aftosa”. Propuesta del grupo técnico de expertos sobre requisitos mínimos de bioseguridad para proveedores del Banco y mecanismo de evaluación. Banco Regional de Antígenos y Vacunas de Fiebre Aftosa. Presentado en Centro Panamericano de Fiebre Aftosa. 42. Reunión Ordinaria de la Comisión Sudamericana para la Lucha contra la Fiebre Aftosa (COSALFA 42). Quito, Ecuador, 16-17 abr. 2015. http://www.panaftosa.org/cosalfa42/dmdocuments/7%20COSALFA%2042%20Proyecto%20Banco%20Regional_RA. pdf Cosivi O. Informe de la Secretaria. Presentado en 42. Reunión Ordinaria de la Comisión Sudamericana para la Lucha contra la Fiebre Aftosa (COSALFA 42). Quito, Ecuador, 16-17 abr. 2015. http://www.panaftosa.org/cosalfa42/dmdocuments/1%20COSALFA%2042_Informe%20de%20Secretaria%20-%20 OCosivi.pdf Cosivi O. Reporte de PANAFTOSA sobre el Proyecto “Banco Regional de antígenos/vacuna de Fiebre Aftosa”. Introducción. Presentado en Centro Panamericano de Fiebre Aftosa. 42. Reunión Ordinaria de la Comisión Sudamericana para la Lucha contra la Fiebre Aftosa (COSALFA 42). Quito, Ecuador, 16-17 abr. 2015. http://www.panaftosa.org/cosalfa42/dmdocuments/6%20COSALFA%2042_BANVACO_OC.pdf Pompei J. Estrategias y Desafíos. Visión de PANAFTOSA. Desafíos de la última fase del Plan de Acción del PHEFA 2011-2020: La transición de los estatus de libre con para libre sin vacunación. Presentado en Centro Panamericano de Fiebre Aftosa. 42. Reunión Ordinaria de la Comisión Sudamericana para la Lucha contra la Fiebre Aftosa (COSALFA 42). Quito, Ecuador, 16-17 abr. 2015. http://www.panaftosa.org/cosalfa42/dmdocuments/21%20COSALFA%2042_Panaftosa_JP.pdf Pompei J. Reporte de la Cooperación Técnica (CT) de PANAFTOSA en Fiebre Aftosa – año 2014. Países y Proyectos - Laboratorio de Producción. Presentado en Centro Panamericano de Fiebre Aftosa. 42. Reunión Ordinaria de la Comisión Sudamericana para la Lucha contra la Fiebre Aftosa (COSALFA 42). Quito, Ecuador, 16-17 abr. 2015. http://www.panaftosa.org/cosalfa42/dmdocuments/3%20COSALFA%2042_Reporte%20Cooperacion%20tecnica_JP. pdf Sanchez Vazquez MJ. Reporte de PANAFTOSA sobre el Proyecto “Banco Regional de antígenos/vacuna de Fiebre Aftosa”. Resultados preliminares del análisis de riesgo para definir las cepas virales a ser incluidas en el Banco Regional. Planteamiento de la estrategia de análisis de riesgo de introducción del virus de fiebre aftosa en la región de Sudamérica y Panamá. Presentado en Centro Panamericano de Fiebre Aftosa. 42. Reunión Ordinaria de la Comisión Sudamericana para la Lucha contra la Fiebre Aftosa (COSALFA 42). Quito, Ecuador, 16-17 abr. 2015. http://www.panaftosa.org/cosalfa42/dmdocuments/7a%20COSALFA42_Analisis%20de%20Riesgo_M%20Sanchez.p df Sanchez Vazquez MJ. Situación Sanitaria de los Programas Nacionales de erradicación de la Fiebre Aftosa. Presentado en Centro Panamericano de Fiebre Aftosa. 42. Reunión Ordinaria de la Comisión Sudamericana para la Lucha contra la Fiebre Aftosa (COSALFA 42). Quito, Ecuador, 16-17 abr. 2015. http://www.panaftosa.org/cosalfa42/dmdocuments/2%20COSALFA%2042%20Informe%20Situacion%20Sanitaria_ MS_CORRIGIDA.pdf Allende R. Estrategias de Prevención y Contingencia en la región de las Américas. Banco de Antígenos / Vacunas. Presentado en Seminario Internacional Pre COSALFA “Consolidando el Estatus Libre de Fiebre Aftosa de la Región de Sudamérica: Planes de Prevención, Vigilancia y Contingencia”. Quito, Ecuador, 13-14 abr. 2015. http://www.panaftosa.org/cosalfa42/dmdocuments/Tema%205%20Seminario%20PreCosalfa%2042_Rossana%20A llende.pdf Buzanovsky LP , Sanchez Vazquez MJ, Martini M, Naranjo J, Pompei J. Utilización de Sistemas de Información Geográfica en el cotidiano de los servicios de vigilancia agropecuaria. Experiencias de las oficinas del Proyecto CAF-OPS fortalecimiento acciones prevención Fiebre Aftosa zona fronteriza Ecuador – Perú. Presentado en Seminario Internacional Pre COSALFA “Consolidando el Estatus Libre de Fiebre Aftosa de la Región de Sudamérica: Planes de Prevención, Vigilancia y Contingencia”. Quito, Ecuador, 13-14 abr. 2015. http://www.panaftosa.org/cosalfa42/dmdocuments/3%20Lia%20Buzanovsky%20Panaftosan%20poster2_Panaftos a%20cosalfa42%20A.pdf http://www.panaftosa.org/cosalfa42/dmdocuments/1%20Poster_CAF_SIG_Cosalfa_revisado.pdf

OIE Reference Laboratory Reports Activities, 2015

7

Foot and mouth disease - Rossana Allende - brazil Garcia R. Últimos brotes de Fiebre Aftosa en Países con certificación de libres en Sudamérica: Lecciones aprendidas. Presentado en Seminario Internacional Pre COSALFA “Consolidando el Estatus Libre de Fiebre Aftosa de la Región de Sudamérica: Planes de Prevención, Vigilancia y Contingencia”. Quito, Ecuador, 13-14 abr. 2015. http://www.panaftosa.org/cosalfa42/dmdocuments/Tema%202_Seminario_PreCosalfa42_Rodrigo%20Garcia.pdf Naranjo J. La situación de vulnerabilidad y percepción de riesgo de Fiebre Aftosa en Sudamérica. Introducción. Presentado en Seminario Internacional Pre COSALFA “Consolidando el Estatus Libre de Fiebre Aftosa de la Región de Sudamérica: Planes de Prevención, Vigilancia y Contingencia”. Quito, Ecuador, 13-14 abr. 2015. http://www.panaftosa.org/cosalfa42/dmdocuments/Tema%203%20Seminario%20Pre%20Cosalfa42_Jose%20Nara njo.pdf Pompei J. Perspectivas y etapas a seguir para lograr la situación de Libre Sin Vacunación en Sudamérica. Presentado en Seminario Internacional Pre COSALFA “Consolidando el Estatus Libre de Fiebre Aftosa de la Región de Sudamérica: Planes de Prevención, Vigilancia y Contingencia”. Quito, Ecuador, 13-14 abr. 2015. http://www.panaftosa.org/cosalfa42/dmdocuments/Tema%204%20Seminario%20Pre-COSALFA42_Julio%20Pompei .pdf Rivera A. Estrategias de Prevención y Contingencia en la región de las Américas. Introducción. Presentado en Seminario Internacional Pre COSALFA “Consolidando el Estatus Libre de Fiebre Aftosa de la Región de Sudamérica: Planes de Prevención, Vigilancia y Contingencia”. Quito, Ecuador, 13-14 abr. 2015. http://www.panaftosa.org/cosalfa42/dmdocuments/Tema%205%20Seminario%20PreCosalfa%2042_Alejandro%20 Rivera.pdf Sanchez Vazquez MJ. Experiencias extra regionales de emergencias sanitarias en Fiebre Aftosa: Lecciones para las Américas. Introducción al tema. Tema I: Experiencias en emergencias de Fiebre Aftosa; Lecciones aprendidas que pueden ser útiles para las Américas. Presentado en Seminario Internacional Pre COSALFA “Consolidando el Estatus Libre de Fiebre Aftosa de la Región de Sudamérica: Planes de Prevención, Vigilancia y Contingencia”. Quito, Ecuador, 13-14 abr. 2015. http://www.panaftosa.org/cosalfa42/dmdocuments/Tema%201_Seminario_PreCosalfa_Manuel%20Sanchez%20Pan aftosa.pdf Rivera A. Guía Técnica de Trabajo para la Última Etapa del Programa Hemisférico de Erradicación de Fiebre Aftosa – PHEFA. Presentado en 5ª Reunión Extraordinaria de la Comisión Sudamericana de la Lucha Contra la Fiebre Aftosa. Resoluciones. Cuiabá, Mato Grosso, 19 de octubre del 2015. http://www.panaftosa.org/cosalfaextra5/dmdocuments/Guia_Tecnica_[18.10.15-00.46].pdf Allende R.M. Vacina de Febre Aftosa e testes DIVA. XI Congreso Brasilero de Buiatria e XII Congreso Latinoamericano de Buiatria. SP, Brasil 22-24 Julio 2015 c) National conferences: 1 Allende R.M. Vacina de Febre Aftosa e testes DIVA. XI Congreso Brasilero de Buiatria e XII Congreso Latinoamericano de Buiatria. SP, Brasil 22-24 Julio 2015 d) Other: (Provide website address or link to appropriate information) 5 Centro Panamericano de Fiebre Aftosa . Informe Epidemiológico Semanal sobre Enfermedad Similar al Colera Porcino Centro Panamericano de Fiebre Aftosa . Informe Epidemiológico Semanal sobre Fiebre Aftosa y Estomatitis Vesicular Centro Panamericano de Fiebre Aftosa . Informe Epidemiológico Semanal sobre Síndromes Compatibles con Encefalitis Equina Centro Panamericano de Fiebre Aftosa. Boletín de Fiebre Aftosa y Enfermedades Vesiculares. http://www.paho.org/bulletins/index.php?option=com_jnews&act=mailing&task=archive&listid=139&listype=1&I temid=276&lang=es Centro Panamericano de Fiebre Aftosa. Laboratorio de Referencia. Procedimiento para colecta y remisión de muestras para el diagnóstico de enfermedades vesiculares y su diagnóstico diferencial. Rio de Janeiro; PANAFTOSA-OPS/OMS; 2015. http://bvs1.panaftosa.org.br/local/File/textoc/Enfermedades_Vesiculares_Procedimiento_colecta_remision_muestra s_V3-Julio2015.pdf

8

OIE Reference Laboratory Reports Activities, 2015

Foot and mouth disease - Rossana Allende - brazil

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries? Yes a) Technical visits: 2 b) Seminars: 1 c) Hands-on training courses: 5 d) Internships (>1 month): 1 Type of technical training provided (a, b, c or d)

Country of origin of the expert(s) provided with training

No. participants from the corresponding country

a

Brazil, Japan

2, 1

b

Argentina, Brasil, Bolivia, Chile, Colombia, Ecuador,Paraguay, Perú, Uruguay, Venezuela

140 (total)

c

Brazil, Paraguay, Mexico,Venezuela,

26, 8, 1, 3

d

Brazil

1

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System certified according to an International Standard? No Explain Quality Management System in adoption process or currently in place PANAFTOSA is in adoption process for ISO 17025

16. Is your laboratory accredited by an international accreditation body? No 17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned? Yes (See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2014, Chapter 1.1.3a)

OIE Reference Laboratory Reports Activities, 2015

9

Foot and mouth disease - Rossana Allende - brazil

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE? No

19. Did your laboratory participate in scientific meetings on behalf of the OIE? No

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease? Yes 21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests? Yes

Role of your Reference Laboratory (organiser/ participant)

No. participants

Participating OIE Ref. Labs/ organising OIE Ref. Lab.

Determining capability of laboratories to conduct FMD antigen detection tests

participant

unknown

Organized by Pirbright/UK laboratory

Determining laboratory's capability to conduct FMD antibody detection tests

participant

unknown

Organized by Pirbright/UK

Purpose of the proficiency tests:

1

1

validation of a diagnostic protocol: specify the test; quality control of vaccines: specify the vaccine type, etc.

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest? No

10

OIE Reference Laboratory Reports Activities, 2015

Foot and mouth disease - Rossana Allende - brazil

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease? Yes Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing see point 1.3

Purpose for inter-laboratory test comparisons1

Determining laboratory's capability to conduct FMD/VSV molecular diagnosis tests

No. participating laboratories

Region(s) of participating OIE Member Countries Africa Americas Asia and Pacific Europe Middle East

10

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE? Yes

Kind of consultancy

Location

Subject (facultative)

ad hoc Group meeting 6-8 October 2015

Paris, France

FMD

ad hoc Group meeting 30 Nov - 03 Dec 2015

Paris, France

FMD

25. Additional comments regarding your report:

OIE Reference Laboratory Reports Activities, 2015

11